Loading…
Biohaven Ltd. is projected to rise to $18.13 by 2027, a +17% move from its current price of $15.55. BHVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $14.89 | $15.57 | $16.28 | +0.10% |
| Jul 13 | $14.63 | $15.58 | $16.60 | +0.20% |
| Jul 14 | $14.44 | $15.60 | $16.85 | +0.29% |
| Jul 15 | $14.28 | $15.61 | $17.07 | +0.39% |
| Jul 16 | $14.14 | $15.63 | $17.27 | +0.49% |
| Jul 17 | $14.02 | $15.64 | $17.45 | +0.59% |
| Jul 18 | $13.91 | $15.66 | $17.62 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.91 | $15.66 | $17.62 | +0.68% |
| Week 2 | $13.34 | $15.76 | $18.63 | +1.37% |
| Week 3 | $12.94 | $15.87 | $19.47 | +2.07% |
| Week 4 | $12.62 | $15.98 | $20.24 | +2.76% |
| Week 5 | $12.36 | $16.09 | $20.95 | +3.47% |
| Week 6 | $12.13 | $16.20 | $21.63 | +4.18% |
| Week 7 | $11.93 | $16.31 | $22.29 | +4.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd.
and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Biohaven Ltd. (BHVN) is a healthcare company focused on developing therapies across immunology, neuroscience, and oncology. It currently trades at $16.64 per share with a market cap of $2.51B and a rank of 1887 by market capitalization.
A major floor 51.8% below — a decisive break under it would weaken the trend.
The nearest floor, 34.9% below — buyers have tended to step in here.
The nearest ceiling, 8.0% above — a clean break opens room to run.
A major ceiling 33.9% above — clearing it would confirm fresh momentum.
Key BHVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BHVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.12 | Sell | $16.01 | Sell |
| MA 10 | $15.80 | Sell | $15.66 | Sell |
| MA 20 | $14.63 | Buy | $14.68 | Buy |
| MA 50 | $11.81 | Buy | $12.79 | Buy |
| MA 100 | $10.92 | Buy | $11.92 | Buy |
| MA 200 | $11.63 | Buy | $13.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.06 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 44.70 | Neutral |
| Williams %R (14) | -61.69 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 5.21 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 38.31 | Neutral |
| TRIX (15) | 1.63 | Buy |
| Awesome (5,34) | 3.12 | Buy |
| Ultimate (7,14,28) | 59.90 | Neutral |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 16.47 | Sell |
| ADX (14) | 31.58 | Buy |
| ATR (14) | 0.56 | Info |
The near-term technical picture shows a bullish tilt despite momentum nearing overbought levels. RSI14 is 70, suggesting stretched momentum, while the 30-day range spans $12.41 to $22.31. The moving averages put the stock above recent baselines, with SMA50 at $11.55 and SMA200 at $11.62, indicating a constructive trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.09 | $15.55 | $24.71 | 0% | Neutral | |
| $13.58 | $18.13 | $26.04 | +17% | Neutral | |
| $17.17 | $24.07 | $36.54 | +55% | Bullish | |
| $22.45 | $32.80 | $51.95 | +111% | Bullish | |
| $22.72 | $34.45 | $56.54 | +122% | Bullish | |
| $23.63 | $37.08 | $62.75 | +138% | Bullish | |
| $22.26 | $36.09 | $62.75 | +132% | Bullish | |
| $22.42 | $37.50 | $66.81 | +141% | Bullish | |
| $29.36 | $50.59 | $92.19 | +225% | Bullish | |
| $34.27 | $60.80 | $113.10 | +291% | Bullish | |
| $37.71 | $76.75 | $155.45 | +394% | Bullish | |
| $76.08 | $169.08 | $386.38 | +987% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.09 | $15.55 | $18.77 | +0.00% |
| August 2026 | $13.69 | $16.45 | $20.49 | +5.78% |
| September 2026 | $13.99 | $16.99 | $21.54 | +3.32% |
| October 2026 | $13.68 | $16.79 | $21.59 | -1.22% |
| November 2026 | $14.18 | $17.55 | $22.85 | +4.54% |
| December 2026 | $15.04 | $18.76 | $24.71 | +6.91% |
Click any year to see its month-by-month BHVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BHVN price prediction for 2026 points to an average of $15.55 (low $8.09, high $24.71) — a potential gain of 0% on today's $15.55. A consolidation phase looks the most probable path here.
In 2027, BHVN is projected to trade between $13.58 and $26.04, averaging $18.13 — a potential gain of +17% from today's $15.55. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
Biohaven Ltd.'s 2028 outlook centres on $24.07, within a $17.17 to $36.54 range. That is up +33% on the projected 2027 average. That marks a +55% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, BHVN could reach as high as $51.95, with a base case around $32.80 and support toward $22.45 — roughly +111% from $15.55. Momentum favours further upside here.
Expect BHVN to range from $22.72 to $56.54 through 2030. The $34.45 average target implies a +122% move from current prices. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The BHVN price prediction for 2031 points to an average of $37.08 (low $23.63, high $62.75) — a potential gain of +138% on today's $15.55. Momentum favours further upside here.
In 2032, BHVN is projected to trade between $22.26 and $62.75, averaging $36.09 — a potential gain of +132% from today's $15.55. That is -3% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Biohaven Ltd.'s 2033 outlook centres on $37.50, within a $22.42 to $66.81 range. That is up +4% on the projected 2032 average. That marks a +141% change versus current levels. Momentum favours further upside here.
By 2034, BHVN could reach as high as $92.19, with a base case around $50.59 and support toward $29.36 — roughly +225% from $15.55. Buyers look set to stay in control over this stretch.
Expect BHVN to range from $34.27 to $113.10 through 2035. The $60.80 average target implies a +291% move from current prices. That is up +20% on the projected 2034 average. Momentum favours further upside here.
The BHVN price prediction for 2040 points to an average of $76.75 (low $37.71, high $155.45) — a potential gain of +394% on today's $15.55. Buyers look set to stay in control over this stretch.
In 2050, BHVN is projected to trade between $76.08 and $386.38, averaging $169.08 — a potential gain of +987% from today's $15.55. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BHVN today (≈ 64.308682 BHVN) could be worth
$10,873.02
+$9,873.02 (+987%) by 2050 · US Dollar
Based on the average projected BHVN price of $169.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BHVNwould be worth at today's price.
$1,000 invested in BHVN on Jul 10, 2025 (≈ 66.533601 BHVN) would be worth
$1,034.6
+$34.6 (+3.5%) today · 1.03× · US Dollar
Based on a BHVN entry price of $15.03 vs. today's $15.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.96 | $974.31 | -2.6% |
| 1 month ago | $11.07 | $1,404.7 | +40.5% |
| 3 months ago | $9.17 | $1,695.75 | +69.6% |
| 6 months ago | $11.84 | $1,313.34 | +31.3% |
| 1 year ago | $15.03 | $1,034.6 | +3.5% |
| All time (3.8y) ago | $7.14 | $2,179.13 | +117.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BHVN forecast.
Our base-case forecast reaches $31.00 around 2029.
Implied market cap at $31.00: $4.67B
The year-by-year forecast presents a rising average price from 2026 through 2050, signaling meaningful upside ahead. The 2026 average is $16.64 with a neutral sentiment, followed by bullish momentum in 2027 (avg $20.30) and beyond. By 2030 the average is $40.44 and the 2050 average reaches $228.04, with corresponding max prices up to $66.31 in 2030 and $520.17 in 2050.
Returns compound from 2027 onward, with ROI figures of 22% (2027), 69.2% (2028), 130.7% (2029), 143% (2030), 166.3% (2031), 163.1% (2032), 179.1% (2033), 289.1% (2034), 362.9% (2035), 521.1% (2040), and 1270.5% (2050). The outlook remains bullish through 2050, though these are estimates and not guarantees, reflecting market expectations for growth and volatility.
Tap a question to reveal the answer.
Avg $40.44; min $26.70; max $66.31; ROI 143%; sentiment BULLISH.
The forecast shows a bullish trend from 2027 onward with rising averages and positive ROI (e.g., 2027 Avg $20.30, ROI 22%; 2028 Avg $28.15, ROI 69.2%; 2029 Avg $38.39, ROI 130.7%; 2050 Avg $228.04, ROI 1270.5%). These are estimates, not guarantees.
Yes. The forecast shows higher max prices in later years, including $117.83 in 2034, $143.10 in 2035, $209.00 in 2040, and $520.17 in 2050.
Current price is $16.64 and market cap is $2.51B.
30-day range is $12.41 to $22.31. RSI14 is 70. SMA50 is $11.55, SMA200 is $11.62. Support is $10.07 and resistance is $16.64.
Biohaven Ltd. Community Discussion
0Share your Biohaven Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.